All productsTesamorelin
Size
- 20 mg — $150.00 CAD — Available
Research focus
A growth-hormone-releasing factor analogue studied in HIV-associated abdominal fat accumulation.
In simple words
Tesamorelin is a peptide modelled on a signal that stimulates growth-hormone release. The selected clinical research concerns abdominal fat accumulation in people living with HIV, not general fitness outcomes.
The named research compound is described here; the identity and formulation of this catalogue vial have not been independently verified.
Research references
Reviewed 2026-10-26
Human — randomized trial with extension
404 people with HIV and excess abdominal fat in the context of antiretroviral treatment.
The growth-hormone-releasing factor analogue reduced visceral fat in the studied population and increased IGF-I.
Benefits were lost after switching to placebo. A specific clinical population cannot establish general fat-loss benefits. Although tolerability was reported, long-term safety and this vial are not established.
PMID 20101189. Indexed abstract checked through Europe PMC on 2026-10-26. Selected evidence, not a systematic review.
Resources
Compound name and formula checked via PubChem PUG REST. This reference does not verify the vial, salt or formulation.
PubChemMechanism and target search. Automated access returned 403; DrugBank was not used to substantiate claims or approval status.
DrugBankProtein/precursor search, not a record of the supplied vial. Synthetic compounds and lab supplies may have no matching protein entry.
UniProtBioactivity search. Assay results depend on the tested compound, target and experimental conditions.
ChEMBLExplore indexed literature. Search results are not supporting citations; selected verified publications appear above.
PubMedExplore registrations. A match or completed study does not establish efficacy, approval or relevance to this vial.
ClinicalTrials.govEvidence on studied compounds does not establish the identity, purity, safety, or regulatory approval of the catalogue vial. No Canadian regulatory status is assessed here.
Research questions about Tesamorelin
What is Tesamorelin?
Tesamorelin is a peptide modelled on a signal that stimulates growth-hormone release. The selected clinical research concerns abdominal fat accumulation in people living with HIV, not general fitness outcomes.
What types of research are cited for Tesamorelin?
The Tesamorelin profile contains the following selected evidence. This is not a systematic review or a complete inventory of research.
Tesamorelin and visceral fat in HIV (2010): Human — randomized trial with extension
Publication: Tesamorelin and visceral fat in HIVWho or what was studied in the selected Tesamorelin references?
Tesamorelin and visceral fat in HIV (2010): 404 people with HIV and excess abdominal fat in the context of antiretroviral treatment.
Publication: Tesamorelin and visceral fat in HIVWhat identity distinctions matter for Tesamorelin?
The named research compound is described here; the identity and formulation of this catalogue vial have not been independently verified.
What do the selected Tesamorelin studies not establish?
Tesamorelin and visceral fat in HIV (2010): Benefits were lost after switching to placebo. A specific clinical population cannot establish general fat-loss benefits. Although tolerability was reported, long-term safety and this vial are not established.
Publication: Tesamorelin and visceral fat in HIVThese studies do not establish the identity, purity, safety or effects of the MXC Tesamorelin vial. Findings in one formulation, population or experimental model should not be assumed to apply to another.